Press Releases

Cannara Biotech Inc., a vertically integrated producer of premium-grade cannabis and derivative products with one of the largest indoor cannabis cultivation facilities in Canada and the largest in Quebec, today announced that it has entered into a definitive agreement (the "Transaction") to acquire a one million square foot licensed cultivation and manufacturing facility in Valleyfield, Quebec ("Valleyfield Facility") from Medican Organic Inc., a wholly-owned subsidiary of

Bio-Techne Corporation, a leader in developing innovative tools and technologies for cell and gene therapy research and manufacturing, has partnered with Autolomous to implement a first of its kind electronic batch record system, AutoloMATETM, at Bio-Techne's GMP cellular manufacturing center. Through this partnership Bio-Techne will be able to offer state of the art electronic records to therapeutic companies utilizing its non-viral gene delivery system, TcBusterTM, or contract

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that it is set to join the broad-market Russell 3000® Index as well as the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021, according to a preliminary list of additions posted on June 4, 2021, by FTSE Russell, a leading global index provid

WuXi XDC, a global CDMO company dedicated to end-to-end bioconjugates services, and LegoChem Biosciences, today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in development and manufacturing of antibody-drug conjugates (ADCs). Under the partnership, LCB will have access to XDC' integrated services in mAb, linker, payload, analytical and formulation development as well as ADC drug substance and drug product development and manufactu

Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces that the Japan Patent Office has officially allowed the patent of Transgene’s oncolytic virus (OV) backbone VVcopTK-RR- that encodes one or more immune checkpoint inhibitor(s) (ICIs). This authorization in Japan follows similar patent grants obtained in several key other geographies including the US and Europe, providing broad protection of this technology in t

Aimmune Therapeutics, a Nestlé Health Science company developing pharmaceutical therapies to prevent, manage and treat food and metabolic-related diseases, including exocrine pancreatic insufficiency (EPI), today announced the launch of PACT-CP, a Patient-Centric Chronic Pancreatitis Registry study to better understand the unmet needs and therapeutic burden on patients with EPI due to chronic pancreatitis (CP). “One of the key elements in understanding human disease is

Symbiosis Pharmaceutical Services (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals, and headquartered in Stirling, UK, has appointed Jette Cowan as Business Development Manager (BDM) for the Northern region of the European Union (E.U.). As BDM, Jette will be tasked with developing strategic relationships with new and existing clients across the Nordic region and Germany. Co-l

With the new GKF 60, Syntegon Technologysets new standards in lab-scale capsule filling under the motto "GKF 60 - takes your molecule to production"."Researching pharmacists and laboratories need to bring their new drugs to regulatory approval quickly and in a targeted manner. To do so, they need a mobile machine that enables the development of new formulations with a wide variety of dosing systems - flexibly and at different OEB levels," says Matthias Mössinger, Seni

Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. announced new investigational data from the pivotal Phase 3 CLEAR(Study 307)/KEYNOTE-581 trial, which evaluated the combinations of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, N.J., U.S.A., and LENVIMA plus everolimus versus sunitinib for the first-line treatment of patients with advanced renal cell

Entegris, Inc., a world-class supplier of advanced materials and process solutions for the semiconductor and other high-technology industries, today announced the expansion of its Life Sciences manufacturing facilities located in Billerica, MA; Bloomington, MN; and Logan, UT. The expansions are part of Entegris’ capital expenditures plan to invest approximately $30 million in life sciences capacity and capabilities this year, in addition to the $10 million invested in 2020. Th